Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges

Cancer Immunology, Immunotherapy

Volumn 61, Issue 7, 2012, Pages 953-962

  Lipowska Bhalla, Grazyna ^a   Gilham, David E ^a,b   Hawkins, Robert E ^a   Rothwell, Dominic G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer; Chimeric antigen receptor; Gene modification; Immunotherapy; T cell

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CARCINOMA; FEVER; GLIOBLASTOMA; HUMAN; HYPOTENSION; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; REVIEW; SEPSIS; T LYMPHOCYTE; TREATMENT RESPONSE;

CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84862775412     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1254-0     Document Type: Review

References (82)

1. G Gross T Waks Z Eshhar 1989 Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci USA 86 24 10024 10028 2513569 10.1073/pnas.86.24.10024 1:CAS:528:DyaK3cXntFChsw%3D%3D
2. F Garrido T Cabrera A Concha S Glew F Ruiz-Cabello PL Stern 1993 Natural history of HLA expression during tumour development Immunol Today 14 10 491 499 8274189 10.1016/0167-5699(93)90264-L 1:CAS:528:DyaK2cXltFyktA%3D%3D
3. D Mezzanzanica S Canevari A Mazzoni M Figini MI Colnaghi T Waks DG Schindler Z Eshhar 1998 Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells Cancer Gene Ther 5 6 401 407 9917095 1:CAS:528:DyaK1MXmt1KntQ%3D%3D
4. MH Kershaw MW Teng MJ Smyth PK Darcy 2005 Supernatural T cells: genetic modification of T cells for cancer therapy Nat Rev Immunol 5 12 928 940 16322746 10.1038/nri1729 1:CAS:528:DC%2BD2MXht1KntrzL
5. A Murphy JA Westwood MW Teng M Moeller PK Darcy MH Kershaw 2005 Gene modification strategies to induce tumor immunity Immunity 22 4 403 414 15845446 10.1016/j.immuni.2005.03.007 1:CAS:528:DC%2BD2MXktFKru74%3D
6. MK Brenner HE Heslop 2010 Adoptive T cell therapy of cancer Curr Opin Immunol 22 2 251 257 10.1016/j.coi.2010.01.020 20171074 10.1016/j.coi.2010.01. 020 1:CAS:528:DC%2BC3cXks1Srtrk%3D
7. JS Bridgeman RE Hawkins AA Hombach H Abken DE Gilham 2010 Building better chimeric antigen receptors for adoptive T cell therapy Curr Gene Ther 10 2 77 90 20222863 10.2174/156652310791111001 1:CAS:528:DC%2BC3cXms1Sjs7Y%3D
8. M Kalos 2012 Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses Cancer Immunol Immunother 61 1 127 135 10.1007/s00262-011-1173-5 22131062 10.1007/s00262-011-1173-5 1:CAS:528:DC%2BC38Xkt1Wgsw%3D%3D
9. M Chmielewski H Abken 2012 CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer Cancer Immunol Immunother 10.1007/s00262-012-1202-z 22274776
10. RE Bird KD Hardman JW Jacobson S Johnson BM Kaufman SM Lee T Lee SH Pope GS Riordan M Whitlow 1988 Single-chain antigen-binding proteins Science 242 4877 423 426 3140379 10.1126/science.3140379 1:CAS:528:DyaL1MXit12ktLo%3D
11. U Altenschmidt R Kahl D Moritz BS Schnierle B Gerstmayer W Wels B Groner 1996 Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes Clin Cancer Res 2 6 1001 1008 9816261 1:STN:280:DyaK1M%2FjsFWjuw%3D%3D
12. KS Kahlon C Brown LJ Cooper A Raubitschek SJ Forman MC Jensen 2004 Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells Cancer Res 64 24 9160 9166 10.1158/0008-5472.CAN-04-0454 15604287 10.1158/0008-5472.CAN-04-0454 1:CAS:528:DC%2BD2cXhtVOmsb7E
13. T Zhang BA Lemoi CL Sentman 2005 Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy Blood 106 5 1544 1551 10.1182/blood-2004-11-4365 15890688 10.1182/blood-2004-11-4365 1:CAS:528:DC%2BD2MXps1OgsL4%3D
14. T Zhang A Barber CL Sentman 2007 Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways Cancer Res 67 22 11029 11036 10.1158/0008-5472.CAN-07-2251 18006849 10.1158/0008-5472.CAN-07-2251 1:CAS:528:DC%2BD2sXhtlSlsLvI
15. MC Gong JB Latouche A Krause WD Heston NH Bander M Sadelain 1999 Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen Neoplasia 1 2 123 127 10933046 10.1038/sj.neo.7900018 1:CAS:528:DyaK1MXmslGgu74%3D
16. HM Finney AD Lawson CR Bebbington AN Weir 1998 Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product J Immunol 161 6 2791 2797 9743337 1:CAS:528:DyaK1cXmtVKjt78%3D
17. Darcy PK, Kershaw MH, Trapani JA, Smyth MJ (1998) Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 28(5):1663-1672. doi: 10.1002/(SICI)1521-4141(199805)28:05<1663::AID- IMMU1663>3.0.CO;2-L
18. SD Patel M Moskalenko D Smith B Maske MH Finer JG McArthur 1999 Impact of chimeric immune receptor extracellular protein domains on T cell function Gene Ther 6 3 412 419 10.1038/sj.gt.3300831 10435091 10.1038/sj.gt.3300831 1:CAS:528:DyaK1MXhs1ygsbo%3D
19. A Hombach R Sircar C Heuser T Tillmann V Diehl W Kruis C Pohl H Abken 1998 Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains Int J Mol Med 2 1 99 103 9854151 1:CAS:528:DyaK1cXmvFansLs%3D
20. RD Guest RE Hawkins N Kirillova EJ Cheadle J Arnold A O'Neill J Irlam KA Chester JT Kemshead DM Shaw MJ Embleton PL Stern DE Gilham 2005 The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens J Immunother 28 3 203 211 15838376 10.1097/01.cji.0000161397.96582.59 1:CAS:528:DC%2BD2MXjtlKlurc%3D
21. AA Hombach V Schildgen C Heuser R Finnern DE Gilham H Abken 2007 T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells J Immunol 178 7 4650 4657 17372024 1:CAS:528: DC%2BD2sXjt1WksLY%3D
22. Z Eshhar T Waks G Gross DG Schindler 1993 Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci USA 90 2 720 724 8421711 10.1073/pnas.90.2.720 1:CAS:528:DyaK3sXitVCkurY%3D
23. Z Eshhar T Waks A Bendavid DG Schindler 2001 Functional expression of chimeric receptor genes in human T cells J Immunol Methods 248 1-2 67 76 11223069 10.1016/S0022-1759(00)00343-4 1:CAS:528:DC%2BD3MXht12gu7g%3D
24. JS Bridgeman RE Hawkins S Bagley M Blaylock M Holland DE Gilham 2010 The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex J Immunol 184 12 6938 6949 10.4049/jimmunol.0901766 20483753 10.4049/jimmunol.0901766 1:CAS:528:DC%2BC3cXmvFejsL4%3D
25. L Ren-Heidenreich R Mordini GT Hayman R Siebenlist A LeFever 2002 Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis Cancer Immunol Immunother 51 8 417 423 10.1007/s00262-002-0301-7 12202902 10.1007/s00262-002-0301-7 1:CAS:528:DC%2BD38XovFWktLk%3D
26. NM Haynes MB Snook JA Trapani L Cerruti SM Jane MJ Smyth PK Darcy 2001 Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma J Immunol 166 1 182 187 11123291 1:CAS:528:DC%2BD3MXis1aktQ%3D%3D
27. RJ Brentjens JB Latouche E Santos F Marti MC Gong C Lyddane PD King S Larson M Weiss I Riviere M Sadelain 2003 Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med 9 3 279 286 10.1038/nm827 12579196 10.1038/nm827 1:CAS:528:DC%2BD3sXhsFGgs7k%3D
28. J Maher RJ Brentjens G Gunset I Riviere M Sadelain 2002 Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor Nat Biotechnol 20 1 70 75 11753365 10.1038/nbt0102-70 1:CAS:528:DC%2BD38XislSktw%3D%3D
29. L Alvarez-Vallina RE Hawkins 1996 Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors Eur J Immunol 26 10 2304 2309 10.1002/eji.1830261006 8898938 10.1002/eji.1830261006 1:CAS:528: DyaK28XmsV2nsr4%3D
30. EJ Beecham S Ortiz-Pujols RP Junghans 2000 Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor J Immunother 23 3 332 343 10838662 10.1097/00002371-200005000-00006 1:CAS:528:DC%2BD3cXktVKmtrw%3D
31. RJ Brentjens E Santos Y Nikhamin R Yeh M Matsushita K La Perle A Quintas-Cardama SM Larson M Sadelain 2007 Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts Clin Cancer Res 13 18 Pt 1 5426 5435 10.1158/1078-0432.CCR-07-0674 17855649 10.1158/1078-0432.CCR-07-0674 1:CAS:528:DC%2BD2sXhtVCitLzL
32. D Friedmann-Morvinski A Bendavid T Waks D Schindler Z Eshhar 2005 Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation Blood 105 8 3087 3093 10.1182/blood-2004- 09-3737 15626734 10.1182/blood-2004-09-3737 1:CAS:528:DC%2BD2MXjtlSmtbY%3D
33. A Loskog V Giandomenico C Rossig M Pule G Dotti MK Brenner 2006 Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells Leukemia 20 10 1819 1828 10.1038/sj.leu.2404366 16932339 10.1038/sj.leu.2404366 1:CAS:528: DC%2BD28XhtVOlsbfN
34. NM Haynes JA Trapani MW Teng JT Jackson L Cerruti SM Jane MH Kershaw MJ Smyth PK Darcy 2002 Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors Blood 100 9 3155 3163 12384413 10.1182/blood-2002-04-1041 1:CAS:528:DC%2BD38XosVSisLo%3D
35. JH Pinthus T Waks K Kaufman-Francis DG Schindler A Harmelin H Kanety J Ramon Z Eshhar 2003 Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes Cancer Res 63 10 2470 2476 12750268 1:CAS:528:DC%2BD3sXjslehsb0%3D
36. MW Teng MH Kershaw M Moeller MJ Smyth PK Darcy 2004 Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes Hum Gene Ther 15 7 699 708 15242530 10.1089/1043034041361235 1:CAS:528: DC%2BD2cXlsFajs7o%3D
37. A Hombach D Sent C Schneider C Heuser D Koch C Pohl B Seliger H Abken 2001 T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis Cancer Res 61 5 1976 1982 11280755 1:CAS:528:DC%2BD3MXit1Ogs74%3D
38. MA Pule KC Straathof G Dotti HE Heslop CM Rooney MK Brenner 2005 A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells Mol Ther 12 5 933 941 10.1016/j.ymthe.2005.04.016 15979412 10.1016/j.ymthe.2005.04.016 1:CAS:528:DC%2BD2MXhtFKmtLjK
39. MC Milone JD Fish C Carpenito RG Carroll GK Binder D Teachey M Samanta M Lakhal B Gloss G Danet-Desnoyers D Campana JL Riley SA Grupp CH June 2009 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 17 8 1453 1464 10.1038/mt.2009.83 19384291 10.1038/mt.2009.83 1:CAS:528: DC%2BD1MXkvVWqsLk%3D
40. HM Finney AN Akbar AD Lawson 2004 Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain J Immunol 172 1 104 113 14688315 1:CAS:528:DC%2BD3sXpvFeht74%3D
41. DG Song Q Ye C Carpenito M Poussin LP Wang C Ji M Figini CH June G Coukos DJ Powell Jr. 2011 In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) Cancer Res 71 13 4617 4627 10.1158/0008-5472.CAN-11-0422 21546571 10.1158/0008-5472.CAN-11-0422 1:CAS:528:DC%2BC3MXotlert74%3D
42. C Carpenito MC Milone R Hassan JC Simonet M Lakhal MM Suhoski A Varela-Rohena KM Haines DF Heitjan SM Albelda RG Carroll JL Riley I Pastan CH June 2009 Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci USA 106 9 3360 3365 10.1073/pnas.0813101106 19211796 10.1073/pnas.0813101106 1:CAS:528:DC%2BD1MXivF2jsbw%3D
43. Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE, Gilham DE (2011) Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther. doi: 10.1038/gt.2011.192
44. CJ Fitzer-Attas DG Schindler T Waks Z Eshhar 1998 Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation J Immunol 160 1 145 154 9551966 1:CAS:528:DyaK1cXhtFSktw%3D%3D
45. MH Kershaw JA Westwood LL Parker G Wang Z Eshhar SA Mavroukakis DE White JR Wunderlich S Canevari L Rogers-Freezer CC Chen JC Yang SA Rosenberg P Hwu 2006 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer Clin Cancer Res 12 20 Pt 1 6106 6115 17062687 10.1158/1078-0432.CCR-06-1183 1:CAS:528:DC%2BD28XhtFWhsbnL
46. CH Lamers S Sleijfer AG Vulto WH Kruit M Kliffen R Debets JW Gratama G Stoter E Oosterwijk 2006 Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J Clin Oncol 24 13 e20 e22 16648493 10.1200/JCO.2006.05.9964
47. CH Lamers SC Langeveld CM Groot-van Ruijven R Debets S Sleijfer JW Gratama 2007 Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo Cancer Immunol Immunother 56 12 1875 1883 10.1007/s00262-007-0330-3 17479266 10.1007/s00262-007-0330-3
48. JR Park DL Digiusto M Slovak C Wright A Naranjo J Wagner HB Meechoovet C Bautista WC Chang JR Ostberg MC Jensen 2007 Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol Ther 15 4 825 833 17299405 1:CAS:528:DC%2BD2sXhtVejtLfF
49. MA Pule B Savoldo GD Myers C Rossig HV Russell G Dotti MH Huls E Liu AP Gee Z Mei E Yvon HL Weiss H Liu CM Rooney HE Heslop MK Brenner 2008 Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 11 1264 1270 10.1038/nm.1882 18978797 10.1038/nm.1882 1:CAS:528: DC%2BD1cXhtlCjtLrF
50. BG Till MC Jensen J Wang EY Chen BL Wood HA Greisman X Qian SE James A Raubitschek SJ Forman AK Gopal JM Pagel CG Lindgren PD Greenberg SR Riddell OW Press 2008 Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 112 6 2261 2271 10.1182/blood-2007-12-128843 18509084 10.1182/blood-2007-12- 128843 1:CAS:528:DC%2BD1cXhtFCrurjL
51. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK (2011) Anti-tumor activity and long-term fate of chimeric antigen receptor positive T-cells in patients with neuroblastoma. Blood. doi: 10.1182/blood-2011-05-354449
52. DL Porter BL Levine M Kalos A Bagg CH June 2011 Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 8 725 733 10.1056/NEJMoa1103849 21830940 10.1056/NEJMoa1103849 1:CAS:528: DC%2BC3MXhtV2lu7nP
53. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA (2011) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. doi: 10.1182/blood-2011-10-384388
54. M Kalos BL Levine DL Porter S Katz SA Grupp A Bagg CH June 2011 T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 95 95ra73 21832238 10.1126/scitranslmed.3002842 1:CAS:528:DC%2BC3MXhtFOisL3N
55. RJ Brentjens I Riviere JH Park ML Davila X Wang J Stefanski C Taylor R Yeh S Bartido O Borquez-Ojeda M Olszewska Y Bernal H Pegram M Przybylowski D Hollyman Y Usachenko D Pirraglia J Hosey E Santos E Halton P Maslak D Scheinberg J Jurcic M Heaney G Heller M Frattini M Sadelain 2011 Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 118 18 4817 4828 10.1182/blood-2011-04-348540 21849486 10.1182/blood-2011-04-348540 1:CAS:528:DC%2BC3MXhsVOgsrjL
56. JN Kochenderfer WH Wilson JE Janik ME Dudley M Stetler-Stevenson SA Feldman I Maric M Raffeld DA Nathan BJ Lanier RA Morgan SA Rosenberg 2010 Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 20 4099 4102 10.1182/blood-2010-04-281931 20668228 10.1182/blood-2010-04-281931 1:CAS:528:DC%2BC3cXhsFCiu7fK
57. B Savoldo CA Ramos E Liu MP Mims MJ Keating G Carrum RT Kamble CM Bollard AP Gee Z Mei H Liu B Grilley CM Rooney HE Heslop MK Brenner G Dotti 2011 CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients J Clin Invest 121 5 1822 1826 10.1172/JCI46110 21540550 10.1172/JCI46110 1:CAS:528:DC%2BC3MXlvFKnt7o%3D
58. R Brentjens R Yeh Y Bernal I Riviere M Sadelain 2010 Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial Mol Ther 18 4 666 668 10.1038/mt.2010.31 20357779 10.1038/mt.2010.31 1:CAS:528:DC%2BC3cXktVGju74%3D
59. RA Morgan JC Yang M Kitano ME Dudley CM Laurencot SA Rosenberg 2010 Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 4 843 851 10.1038/mt.2010.24 20179677 10.1038/mt.2010.24 1:CAS:528: DC%2BC3cXitlaitb4%3D
60. HJ Kolb 2008 Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood 112 12 4371 4383 10.1182/blood-2008-03-077974 19029455 10.1182/blood-2008-03-077974 1:CAS:528:DC%2BD1cXhsVCltbzO
61. F Ciceri C Bonini MT Stanghellini A Bondanza C Traversari M Salomoni L Turchetto S Colombi M Bernardi J Peccatori A Pescarollo P Servida Z Magnani SK Perna V Valtolina F Crippa L Callegaro E Spoldi R Crocchiolo K Fleischhauer M Ponzoni L Vago S Rossini A Santoro E Todisco J Apperley E Olavarria S Slavin EM Weissinger A Ganser M Stadler E Yannaki A Fassas A Anagnostopoulos M Bregni CG Stampino P Bruzzi C Bordignon 2009 Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study Lancet Oncol 10 5 489 500 10.1016/S1470-2045(09)70074-9 19345145 10.1016/S1470-2045(09)70074- 9
62. MC Jensen L Popplewell LJ Cooper D DiGiusto M Kalos JR Ostberg SJ Forman 2010 Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans Biol Blood Marrow Transplant 16 9 1245 1256 10.1016/j.bbmt.2010.03.014 20304086 10.1016/j.bbmt.2010.03.014 1:CAS:528:DC%2BC3cXpvVOhtr4%3D
63. V Hoyos B Savoldo C Quintarelli A Mahendravada M Zhang J Vera HE Heslop CM Rooney MK Brenner G Dotti 2010 Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety Leukemia 24 6 1160 1170 10.1038/leu.2010.75 20428207 10.1038/leu.2010.75 1:CAS:528:DC%2BC3cXntFShs74%3D
64. M Sadelain I Riviere R Brentjens 2003 Targeting tumours with genetically enhanced T lymphocytes Nat Rev Cancer 3 1 35 45 12509765 10.1038/nrc971 1:CAS:528:DC%2BD38XpvVertbg%3D
65. S Hacein-Bey-Abina C von Kalle M Schmidt F Le Deist N Wulffraat E McIntyre I Radford JL Villeval CC Fraser M Cavazzana-Calvo A Fischer 2003 A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N Engl J Med 348 3 255 256 12529469 10.1056/ NEJM200301163480314
66. C Bonini M Grez C Traversari F Ciceri S Marktel G Ferrari M Dinauer M Sadat A Aiuti S Deola M Radrizzani A Hagenbeek J Apperley S Ebeling A Martens HJ Kolb M Weber F Lotti A Grande E Weissinger JA Bueren M Lamana JH Falkenburg MH Heemskerk T Austin S Kornblau F Marini C Benati Z Magnani S Cazzaniga S Toma C Gallo-Stampino M Introna S Slavin PD Greenberg M Bregni F Mavilio C Bordignon 2003 Safety of retroviral gene marking with a truncated NGF receptor Nat Med 9 4 367 369 10.1038/nm0403-367 12669036 10.1038/nm0403-367 1:CAS:528: DC%2BD3sXisVOmt7Y%3D
67. MK Brenner HE Heslop 2003 Is retroviral gene marking too dangerous to use? Cytotherapy 5 3 190 193 10.1080/14653240310001307 12850996 10.1080/14653240310001307 1:STN:280:DC%2BD3szitVSlsA%3D%3D
68. MB Banasik PB McCray Jr. 2010 Integrase-defective lentiviral vectors: progress and applications Gene Ther 17 2 150 157 10.1038/gt.2009.135 19847206 10.1038/gt.2009.135 1:CAS:528:DC%2BD1MXht12gtrvO
69. G Dotti B Savoldo M Brenner 2009 Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?" Hum Gene Ther 20 11 1229 1239 10.1089/hum.2009.142 19702437 10.1089/hum.2009.142 1:CAS:528:DC%2BD1MXhtlKitLnO
70. DM Barrett Y Zhao X Liu S Jiang C Carpenito M Kalos RG Carroll CH June SA Grupp 2011 Treatment of advanced leukemia in mice with mRNA engineered T cells Hum Gene Ther 22 12 1575 1586 10.1089/hum.2011.070 21838572 10.1089/hum.2011.070 1:CAS:528:DC%2BC3MXhs1ajsb7O
71. PM Rabinovich ME Komarovskaya SH Wrzesinski JL Alderman T Budak-Alpdogan A Karpikov H Guo RA Flavell NK Cheung SM Weissman E Bahceci 2009 Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes Hum Gene Ther 20 1 51 61 10.1089/hum.2008.068 19025415 10.1089/hum.2008.068 1:CAS:528:DC%2BD1MXhtVehtbo%3D
72. PM Rabinovich ME Komarovskaya ZJ Ye C Imai D Campana E Bahceci SM Weissman 2006 Synthetic messenger RNA as a tool for gene therapy Hum Gene Ther 17 10 1027 1035 17007566 10.1089/hum.2006.17.1027 1:CAS:528:DC%2BD28XhtVGgsr%2FN
73. Y Zhao E Moon C Carpenito CM Paulos X Liu AL Brennan A Chew RG Carroll J Scholler BL Levine SM Albelda CH June 2010 Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor Cancer Res 70 22 9053 9061 10.1158/0008-5472.CAN-10- 2880 20926399 10.1158/0008-5472.CAN-10-2880 1:CAS:528:DC%2BC3cXhsVWmsL3F
74. CH Lamers R Willemsen P van Elzakker S van Steenbergen-Langeveld M Broertjes J Oosterwijk-Wakka E Oosterwijk S Sleijfer R Debets JW Gratama 2011 Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells Blood 117 1 72 82 10.1182/blood-2010-07-294520 20889925 10.1182/blood-2010-07-294520 1:CAS:528:DC%2BC3MXhtFGrsLk%3D
75. JA Westwood MJ Smyth MW Teng M Moeller JA Trapani AM Scott FE Smyth GA Cartwright BE Power D Honemann HM Prince PK Darcy MH Kershaw 2005 Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice Proc Natl Acad Sci USA 102 52 19051 19056 10.1073/pnas.0504312102 16365285 10.1073/pnas.0504312102 1:CAS:528:DC%2BD28XivV2hsA%3D%3D
76. H Shibaguchi NX Luo M Kuroki J Zhao J Huang K Hachimine T Kinugasa M Kuroki 2006 A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells Anticancer Res 26 6A 4067 4072 17195459 1:CAS:528:DC%2BD2sXhtFWqsrs%3D
77. LA Welniak BR Blazar WJ Murphy 2007 Immunobiology of allogeneic hematopoietic stem cell transplantation Annu Rev Immunol 25 139 170 10.1146/annurev.immunol.25.022106.141606 17129175 10.1146/annurev.immunol.25. 022106.141606 1:CAS:528:DC%2BD2sXltlagu70%3D
78. A Marcus T Waks Z Eshhar 2011 Redirected tumor-specific allogeneic T cells for universal treatment of cancer Blood 118 4 975 983 10.1182/blood-2011- 02-334284 21653325 10.1182/blood-2011-02-334284 1:CAS:528:DC%2BC3MXhtVWlsbfF
79. CS Hinrichs ZA Borman L Cassard L Gattinoni R Spolski Z Yu L Sanchez-Perez P Muranski SJ Kern C Logun DC Palmer Y Ji RN Reger WJ Leonard RL Danner SA Rosenberg NP Restifo 2009 Adoptively transferred effector cells derived from naive rather than central memory CD8 + T cells mediate superior antitumor immunity Proc Natl Acad Sci USA 106 41 17469 17474 10.1073/pnas.0907448106 19805141 10.1073/pnas.0907448106 1:CAS:528: DC%2BD1MXhs1WktrfI
80. CS Hinrichs ZA Borman L Gattinoni Z Yu WR Burns J Huang CA Klebanoff LA Johnson SP Kerkar S Yang P Muranski DC Palmer CD Scott RA Morgan PF Robbins SA Rosenberg NP Restifo 2011 Human effector CD8 + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy Blood 117 3 808 814 10.1182/blood-2010-05-286286 20971955 10.1182/blood-2010-05-286286 1:CAS:528:DC%2BC3MXhslKksrc%3D
81. CA Klebanoff L Gattinoni DC Palmer P Muranski Y Ji CS Hinrichs ZA Borman SP Kerkar CD Scott SE Finkelstein SA Rosenberg NP Restifo 2011 Determinants of successful CD8 + T-cell adoptive immunotherapy for large established tumors in mice Clin Cancer Res 17 16 5343 5352 10.1158/1078-0432.CCR-11-0503 21737507 10.1158/1078-0432.CCR-11-0503 1:CAS:528:DC%2BC3MXhtVajs7nM
82. S Yang L Gattinoni F Liu Y Ji Z Yu NP Restifo SA Rosenberg RA Morgan 2011 In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells Cancer Immunol Immunother 60 5 739 749 10.1007/s00262-011-0977-7 21305379 10.1007/s00262-011-0977-7 1:CAS:528:DC%2BC3MXkvF2gsL8%3D